title: Risk factors for development of flucloxacillin associated jaundice.
abstract: OBJECTIVE
  To identify risk factors predisposing to the development of flucloxacillin associated jaundice.
  
  
  METHODS
  Case-control study. Medical records of cases and controls were reviewed and information recorded on standard data collection forms.
  
  
  METHODS
  Alfred Hospital recruiting subjects from Melbourne, Sydney, and Brisbane.
  
  
  METHODS
  Cases were defined as patients who had developed jaundice within eight weeks of stopping flucloxacillin, biochemical test results suggesting cholestasis, normal calibre bile ducts, and not been taking recognised hepatotoxic drugs. 51 of the 53 patients referred were included in the study. Four controls for each case were randomly selected from the patient register of the prescribing doctor. These were defined as patients who had been prescribed flucloxacillin without developing jaundice.
  
  
  METHODS
  Demographic characteristics, medical history, indication for flucloxacillin, dose, route and duration of treatment, other drugs, smoking, and previous drug allergies or use of flucloxacillin.
  
  
  RESULTS
  Increasing age and a prolonged duration of flucloxacillin treatment were found to be risk factors for the development of jaundice. Patients aged over 55 years had an odds ratio of 18.61 (95% confidence interval 5.16-67.17) compared with patients under 30. The odds ratio for patients prescribed flucloxacillin for over 14 days was 7.13 (2.90 to 17.58) compared with patients treated for 14 days or less. Dose and route of administration were not related to the risk of jaundice.
  
  
  CONCLUSIONS
  Older patients and those receiving flucloxacillin for longer than two weeks are at a substantially greater risk of jaundice. Careful consideration of the risk-benefit ratio is required when flucloxacillin is used in these settings.
authors.affiliation: Department of Social and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia.
authors.forename: C K
authors.initials: CK
authors.lastname: Fairley
authors.forename: J J
authors.initials: JJ
authors.lastname: McNeil
authors.forename: P
authors.initials: P
authors.lastname: Desmond
authors.forename: R
authors.initials: R
authors.lastname: Smallwood
authors.forename: H
authors.initials: H
authors.lastname: Young
authors.forename: A
authors.initials: A
authors.lastname: Forbes
authors.forename: P
authors.initials: P
authors.lastname: Purcell
authors.forename: I
authors.initials: I
authors.lastname: Boyd
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D016022:Case-Control Studies; D002779:Cholestasis / Q000139:chemically induced*; D004334:Drug Administration Schedule; D005260:Female; D005436:Floxacillin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D005436:Floxacillin